AstraZeneca Reports Five-Year PACIFIC Data for Imfinzi in Stage III NSCLC

AstraZeneca today presented five-year overall survival data from the Phase 3 PACIFIC trial evaluating Imfinzi (durvalumab) as consolidation therapy in patients with unresectable Stage III non-small cell lung cancer following chemoradiotherapy. The data showed that 42.9% of patients in the Imfinzi arm were alive at five years compared to 33.4% in the placebo arm.